Sign inJoin waitlistJoin the waitlist

Dorothy Anna Sipkins

Associate Professor of Medicine · Duke University School of Medicine

Credentials: ·

History

Duke University School of Medicine
Present
Duke University School of Medicine
Present
Duke Cancer Institute
Present

Stanford University School of Medicine
1999

Research

Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging
Nature Medicine · 1998 · First of 6 authors · 668 citations
In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment
Nature · 2005 · First of 9 authors · Corresponding · 644 citations
Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells
Science · 2008 · Last of 6 authors · 483 citations

CM
Chad McCall
3 papers
KL
King Li
3 papers
Sandeep Gurbuxani
3 papers
Andrew Artz
2 papers
EH
Elizabeth Hyjek
2 papers
Koen van Besien
2 papers
LO
Lindsey Olivere
2 papers
Lucy Godley
2 papers
Michael Thirman
2 papers
Monika Burness
2 papers · 1 as a fellow
Olatoyosi Odenike
2 papers
Peter Fecci
2 papers · 1 as a fellow

Grants

Integrin Alpha-6 Drives Metabolic Adaptation and Breast Cancer Survival in Leptomeningeal Metastasis
National Cancer Institute · R01
Contact PI · $626.5K · Duke University
2026–2031
Identifying and Exploiting Therapeutic Vulnerabilities of Tumor-Host Interactions That Drive Bone-to-Meninges Breast Cancer Metastasis
National Cancer Institute · R01
Contact PI · $2.1M · Duke University
2023–2028
Defining and Targeting a Novel Pathway for Central Nervous System Leptomeningeal Metastasis
National Cancer Institute · R01
Contact PI · $1.8M · Duke University
2020–2025
Novel Use of PI3K Inhibition to Prevent Recurrence of B-Cell Acute Lymphoblastic Leukemia
National Cancer Institute · R21
Contact PI · $409.5K · Duke University
2021–2024

Clinical trials

Blincyto Amgen Acrotech BioPharma PH2 Blincyto Marqibo R/R Philadelphi CD19+ ALL
Principal investigator · Withdrawn · Phase 2
Dorothy Sipkins, MD, PhD
2022–2023
Window Trial to Evaluate Molecular Response to PI3K Inhibition With Copanlisib in r/r Adult B-cell ALL
Principal investigator · Terminated · Early phase 1
Dorothy Sipkins, MD, PhD
2021–2023
A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer
Principal investigator · Terminated · Phase 1
GlycoMimetics Incorporated
2019–2021